Results 171 to 180 of about 523,497 (297)

PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)

, 2019
François‐Xavier Mahon, Carla Boquimpani, Nahoto Takahashi, Noam Benyamini, Nelma Clementino, Vasily Shuvaev, J. H. Lipton, Anna Turkina, Raquel De Paz Arias, Beatriz Moiraghi, Franck E. Nicolini, Jolanta Dengler, Tomasz Sacha, D.‐W. Kim, Rafik Fellague-Chebra, Sandip Acharya, Catherine Bouard, Timothy P. Hughes   +17 more
openalex   +1 more source

Neddylation Targets and Stabilizes NLRP3 to Augment Inflammasome‐Mediated Colitis and Mood Disorder

Advanced Science, EarlyView.
NLRP3 inflammasome contributes to colitis and mood disorder. This study demonstrates that neddylation targets NLRP3 at K287, which hinders its interaction with K48‐linked ubiquitination E3 Trim31 and thereby stabilizes it. Neddylation blockade in myeloid cells and microglia mitigates DSS‐induced colitis and psychological stress‐induced anxiety‐like ...
Wenbin Gai, Mengyao Wu, Anbiao Wu, Zhaofei Jing, Zhenjie Ye, Jiayan Jin, Yaolin Zhang, Min Zhao, Genyu Liu, Xu Wang, Xiqin Yang, Jie Dong, Yunlu Xu, Jiyan Zhang   +13 more
wiley   +1 more source

Machine learning-based prediction of progression from idiopathic cytopenia of undetermined significance to myeloid malignancies. [PDF]

Sci Rep
Park H, Han JY, Park HS, Choi Y, Lee JH, Lee JH, Lee KH, Kim YH, Jun TJ, Choi EJ.   +9 more
europepmc   +1 more source

Pregnancy Outcome in Chronic Myeloid Leukemia Patients on Imatinib Therapy

, 2012
S. Shankar, S. Dasgupta, S. Mukhopadhyay, Deepankar Bhattacharya, F.H. Gharami, S. Koner, Uttam Kumar Roy, Jayasri Basak, Ashis Mukhopadhyay   +8 more
openalex   +1 more source

A Unique Chimeric RNA: ERCC1‐iASPP Drives Benzo[a]pyrene‐Induced Lung Carcinogenesis via Dual Coding and Non‐Coding Mechanisms

Advanced Science, EarlyView.
The chimeric RNA ERCC1‐iASPP possesses dual coding and non‐coding functions, synergistically accelerating the process of cellular malignant transformation. Abstract Genetic variation at 19q13.3 critically modulates chemical carcinogen‐induced lung carcinogenesis, particularly in mediating the activity of benzo[a]pyrene (B[a]P), a major polycyclic ...
Mingming Shan, Mingyang Xiao, Liang Zhang, Shen Wang, Jiahang Wu, Kang Cao, Yujin Li, Guopei Zhang, Junwei Xie, Xiaobo Lu   +9 more
wiley   +1 more source

Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and altered bile pathway gene expression. [PDF]

PLoS One
Zhao X, Zhou J, Chyu KY, Erbay E, Cercek B, Shah PK, Dimayuga PC.   +6 more
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma. [PDF]

Front Immunol
Liu H, Wang G, Wang C, Hou D, Li S, Fan Y, Liu B.   +6 more
europepmc   +1 more source

Myeloid Growth Factors [PDF]

Journal of the National Comprehensive Cancer Network, 2011
Jeffrey, Crawford, Jeffrey, Allen, James, Armitage, Douglas W, Blayney, Spero R, Cataland, Mark L, Heaney, Sally, Htoy, Susan, Hudock, Dwight D, Kloth, David J, Kuter, Gary H, Lyman, Brandon, McMahon, David P, Steensma, Saroj, Vadhan-Raj, Peter, Westervelt, Michael, Westmoreland   +15 more
openaire   +2 more sources

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source